A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of YPEG rhEPO, a
recombinant human erythropoietin pegylated by Y shape polyethylene glycol, in patients with
anemia due to Chronic Kidney Disease (CKD) as assessed by hemoglobin maintenance, adverse
events and health-related quality of life.